SCHEMBL6936006

SCHEMBL6936006

CC(=O)NC(CNC(=O)OC(C)(C)C)C(=O)OCc1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.64
TACR1 P25103 1/20 0.52
CTSS P25774 4/20 0.49
PPARA Q07869 1/20 0.49
MAPT P10636 3/20 0.48
POLB P06746 2/20 0.48
MAPK1 P28482 1/20 0.48
GPR55 Q9Y2T6 1/20 0.48
CTSK P43235 4/20 0.47
CTSL P07711 1/20 0.47
CTSB P07858 1/20 0.47
MEN1 O00255 1/20 0.47
RECQL P46063 1/20 0.47
KMT2A Q03164 1/20 0.47
KDM4E B2RXH2 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
ATM Q13315 1/20 0.46
NTSR1 P30989 1/20 0.46
KLK7 P49862 1/20 0.46
KLK5 Q9Y337 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1626508 0.93 SYK (0.67) SYKCTSSPPARAMAPTPOLB
SCHEMBL30460045 0.91 SYK (0.72) SYKCTSSPPARACTSKCTSL
SCHEMBL3897638 0.86 SYK (0.72) SYKCTSSPPARAMAPTCTSK
SCHEMBL7752415 0.86 SYK (0.71) SYKCTSSPPARACTSKCTSL
SCHEMBL479093 0.85 SYK (0.71) SYKCTSSPPARACTSKCTSL
SCHEMBL479092 0.85 SYK (0.71) SYKCTSSPPARACTSKCTSL
SCHEMBL14496968 0.85 SYK (0.71) SYKCTSSPPARACTSKCTSL
SCHEMBL615359 0.84 SYK (0.72) SYKCTSSPPARACTSKCTSL
SCHEMBL615358 0.84 SYK (0.72) SYKCTSSPPARACTSKCTSL
SCHEMBL1890758 0.84 SYK (0.72) SYKCTSSPPARACTSKCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030114488-A1 New processes for producing beta-alanine derivatives FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-06-19 US disclosed
US-6538007-B1 Hydrates and method of antogonizing glycoprotein IIb/IIIa activity using these compounds is also disclosed. antagonist, inhibitor of blood platelets aggregation and inhibitor of the binding of fibrinogen to blood platelets. FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114488-A1 New processes for producing beta-alanine derivatives BCAT1, BCAT2, AGXT SYK 4836/4885TACR1 3251/4885CTSS 746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.